You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The researchers said their analysis of healthcare and exome data identified 285 genes overall that were significantly associated with developmental disorders.
The partners will integrate CCPM's research biobank with personalized genomic information to develop and commercialize the saliva-based tests.
Researchers identified one germline variant near TET2 that appears to be specific to individuals of African ancestry.
PerkinElmer will provide biochemical and genetic testing to support BioMarin's testing program aimed at Batten disease and mucopolysaccharidosis disorders.
Sengenics has largely focused its full-length folded protein arrays technology on research into cancer and autoimmune and infectious disease including COVID-19.
Researchers linked chromatin interactions, super-interactive promoters, and other regulatory features to specific cell types in the developing brain cortex.
FASMAC provides food analysis and biotech products and services, including DNA/RNA synthesis, DNA sequencing, food testing, and genetic analysis reagents.
The investment bank also moved the company's stock price target to $45 from a prior target of $25 and noted several recent acquisitions by Invitae.
Carebox's system matches eligibility criteria from clinical trial databases with patients' health and genomic data to identify potentially relevant studies.
PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.
Centogene will provide its oropharyngeal swabs and conduct RT-PCR testing, while U-Diagnostics will collect samples and report the results.
The company first submitted for 510(k) clearance last year and has received two additional information requests from the agency.
The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.
The firm will deploy 6 million of its rapid point-of-care molecular tests by March 2021, using the money to increase production capacity.
The new guidance allows developers to use other transport media and sample types without first obtaining 510(k) clearance.
The transcriptomic study of human iPSC-derived dopaminergic neurons elucidated how gene expression changed in response to cytotoxic and genetic stressors.
PanCAN has partnered with Tempus to provide panel genomic testing for every patient enrolled in the Precision Promise platform study.
Investors in the round included International Holdings Company (IHC), based in Abu Dhabi, United Arab Emirates, and RPMI Railpen, a UK pension fund.
Other grant recipients include scientists from the University of Chicago, UCLA, UC Santa Barbara, and the University of Washington.
The companies will combine Neogene's expertise in targeting tumor neoantigens with Twist's DNA synthesis platform and product lines.
The company's Q3 sales reflect ongoing demand for COVID-19 testing products and improved customer demand in other areas of the firm's portfolio.
The deal between the two Israeli bioinformatics companies gives BATM a minority stake in Geneyx.
The initiative will build up pathogen sequencing capacity through investment from the Gates Foundation, Microsoft, Illumina, and Oxford Nanopore.
Last week, GenomeWeb's readers were most interested in the FDA's new policy to no longer review SARS-CoV-2 EUA submissions for lab-developed tests.
Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.
The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.
The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.
The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.
In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.